234 related articles for article (PubMed ID: 3938813)
21. Comparative pharmacokinetics of benzodiazepines in dog and man.
Boxenbaum H
J Pharmacokinet Biopharm; 1982 Aug; 10(4):411-26. PubMed ID: 6130139
[TBL] [Abstract][Full Text] [Related]
22. The clinical significance of the effects of cigarette smoking on drug disposition.
Luczynska C; Wilson K
Methods Find Exp Clin Pharmacol; 1983 Sep; 5(7):479-87. PubMed ID: 6366402
[TBL] [Abstract][Full Text] [Related]
23. Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data.
Ashforth EI; Carlile DJ; Chenery R; Houston JB
J Pharmacol Exp Ther; 1995 Aug; 274(2):761-6. PubMed ID: 7636740
[TBL] [Abstract][Full Text] [Related]
24. The use of single sample clearance estimates to probe hepatic drug metabolism: handprinting the influence of cigarette smoking on human hepatic drug metabolism.
Bachmann KA; Nunlee M; Martin M; Schwartz J; Jauregui L; Forney RB
Xenobiotica; 1990 May; 20(5):537-47. PubMed ID: 2112290
[TBL] [Abstract][Full Text] [Related]
25. Interaction between metronidazole and drugs eliminated by oxidative metabolism.
Jensen JC; Gugler R
Clin Pharmacol Ther; 1985 Apr; 37(4):407-10. PubMed ID: 3979002
[TBL] [Abstract][Full Text] [Related]
26. The effect of fenfluramine on disposition and rate of antipyrine elimination.
O'Malley K; Stevenson IH; West M
Pharmacology; 1975; 13(1):12-9. PubMed ID: 1153500
[TBL] [Abstract][Full Text] [Related]
27. Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism.
Lumholtz B; Siersbaek-Nielsen K; Skovsted L; Kampmann J; Hansen JM
Clin Pharmacol Ther; 1975 Jun; 17(6):731-4. PubMed ID: 1139863
[TBL] [Abstract][Full Text] [Related]
28. Defective oxidation of drugs: pharmacokinetic and therapeutic implications.
Eichelbaum M
Clin Pharmacokinet; 1982; 7(1):1-22. PubMed ID: 7042170
[No Abstract] [Full Text] [Related]
29. Prediction of the disposition of beta-lactam antibiotics in humans from pharmacokinetic parameters in animals.
Sawada Y; Hanano M; Sugiyama Y; Iga T
J Pharmacokinet Biopharm; 1984 Jun; 12(3):241-61. PubMed ID: 6438301
[TBL] [Abstract][Full Text] [Related]
30. Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects.
Perucca E; Hebdige S; Frigo GM; Gatti G; Lecchini S; Crema A
Clin Pharmacol Ther; 1980 Dec; 28(6):779-89. PubMed ID: 6777108
[TBL] [Abstract][Full Text] [Related]
31. Clinical relevance of the effect of hepatic disease on drug disposition.
Bond WS
Am J Hosp Pharm; 1978 Apr; 35(4):406-14. PubMed ID: 645712
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of drug metabolism by hydroxylated metabolites: cross-inhibition and specificity.
Soda DM; Levy G
J Pharm Sci; 1975 Dec; 64(12):1928-31. PubMed ID: 1206483
[TBL] [Abstract][Full Text] [Related]
33. Effects of phenobarbital steady state levels on antipyrine clearance and distribution in the rat.
Pei YY; Bialer M; Levy RH
Biopharm Drug Dispos; 1986; 7(1):11-9. PubMed ID: 3955196
[TBL] [Abstract][Full Text] [Related]
34. Prediction of Clearance, Volume of distribution, and Half-life of Drugs in Extremely Low to Low Birth Weight Neonates: An Allometric Approach.
Mahmood I
Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):601-610. PubMed ID: 27562171
[TBL] [Abstract][Full Text] [Related]
35. Drug distribution and binding to muscle in rat.
Yokosuka I; Hayashi M; Awazu S
J Pharmacobiodyn; 1984 Jan; 7(1):43-50. PubMed ID: 6726611
[TBL] [Abstract][Full Text] [Related]
36. Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide.
Williams RL; Blaschke TF; Meffin PJ; Melmon KL; Rowland M
Clin Pharmacol Ther; 1977 Mar; 21(3):301-9. PubMed ID: 837649
[TBL] [Abstract][Full Text] [Related]
37. Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide.
Back DJ; Tjia J; Mönig H; Ohnhaus EE; Park BK
Eur J Clin Pharmacol; 1988; 34(2):157-63. PubMed ID: 3383988
[TBL] [Abstract][Full Text] [Related]
38. Drug metabolism in uremia.
Reidenberg MM
Clin Nephrol; 1975; 4(3):83-5. PubMed ID: 1102176
[No Abstract] [Full Text] [Related]
39. Noninvasive chemical methods of estimating pharmacokinetic parameters.
Graham GG
Pharmacol Ther; 1982; 18(3):333-49. PubMed ID: 6762568
[TBL] [Abstract][Full Text] [Related]
40. Using pharmacokinetics in drug therapy. VII: Pharmacokinetic factors influencing drug therapy in the aged.
Schumacher GE
Am J Hosp Pharm; 1980 Apr; 37(4):559-62. PubMed ID: 6990755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
